scout

ONCOLOGY Vol 10 No 8

By analyzing DNA from a strange mass of tissue found in a man's abdomen, researchers have discovered a previously unknown parasite that can infect and kill humans. The researchers have yet to name the parasite or determine what it looks

The American Cancer Society (ACS) estimates that more than 8 million Americans alive today have a history of cancer, of whom 5 million were diagnosed 5 or more years ago. Most of these 5 million can be considered cured, while others still have evidence of cancer. In 1995, about 1,252,000 new cancer cases were diagnosed. This estimate does not include basal and squamous cell skin cancers and in situ carcinomas except bladder. The annual incidence of these skin cancers is estimated to be more than 800,000 cases. There has been a steady rise in cancer mortality in the United States in the last half-century. In 1995, about 547,000 people died of cancer--more than 1,500 people a day. One out of every five deaths in the United States is from cancer.

Most antibodies do their work in the bloodstream. But others may be powerless to knock out their disease-causing foes unless the confrontation takes place inside an intestinal cell, researchers have found.

The role of elective lymph node dissection in the treatment of patients with early-stage melanoma remains controversial. Some surgeons advocate the routine use of elective node dissection in patients with intermediate-thickness primary tumors, but the cost, morbidity, and low yield of tumor-positive lymph nodes associated with this approach make it less appealing than wide excision and observation. Multiple retrospective studies suggest a survival advantage as high as 25% for patients undergoing elective node dissection in the setting of clinically negative nodes, as opposed to delayed node dissection for clinically evident nodal metastases. Although two randomized prospective studies failed to demonstrate a survival advantage in patients undergoing elective node dissection, as compared with those having wide excision alone, both studies were criticized for their design [1,2].

Drs. North and Spellman concisely review the role of sentinel node biopsy in the management of patients with malignant melanoma and provide an excellent summary of the current state of this technique. A number of comments should be made about this review. These comments relate to (1) the technical aspects of the procedure and (2) its clinical indications.

Drs. Ambrosch and Brinck appropriately emphasize the problems and limitations encountered when using routine pathologic procedures to examine lymph nodes from head and neck cancer specimens. Extraordinary processing techniques have repeatedly yielded a larger number of small nodes and, on occasion, have demonstrated the presence of micrometastases. The majority of these observations come from examination of breast specimens and their axillary dissections. Labor-intensive clearing techniques have varied to some extent, but generally involve progressive removal of opaque fat with alcoholic solvents of increasing percentages culminating in absolute alcohol (100%). Final visualization involves submerging the defatted specimen in cedarwood oil, followed by careful examination and dissection of the backlighted specimen.